UAB - Center for Clinical and Translational Science

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis

Purpose

The purpose of this study is to assess the efficacy, safety, PK, and PD of satralizumab in participants with NMDAR and LGI1 encephalitis.

Conditions

NMDAR Autoimmune Encephalitis
LGI1 Autoimmune Encephalitis

Eligibility

Eligible Ages: Over 12 Years
Eligible Genders: All
Accepts Healthy Volunteers: No

Inclusion Criteria

Reasonable exclusion of tumor or malignancy before baseline visit (randomization) - Onset of AIE symptoms ≤ 9 months before randomization - Meet the definition of "New Onset" or "Incomplete Responder" AIE - For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use adequate contraception during the treatment period and for at least 3 months after the final dose of satralizumab or placebo - For participants enrolled in the extended China enrollment phase at China's sites: participants who are current residents of mainland China, Hong Kong, or Taiwan, and of Chinese ancestry NMDAR AIE Cohort: - Age ≥ 12 years - Diagnosis of probable or definite NMDAR encephalitis LGI1 AIE Cohort - Age ≥ 18 years - Diagnosis of LGI1 encephalitis

Exclusion Criteria

Any untreated teratoma or thymoma at baseline visit (randomization) - History of carcinoma or malignancy, unless deemed cured by adequate treatment with no evidence of recurrence for ≥ 5 years before screening - For participants with NMDAR AIE, history of negative anti-NMDAR antibody in cerebrospinal fluid (CSF) using a cell-based assay within 9 months of symptom onset - Historically known positivity to an intracellular antigen with high cancer association or glutamate decarboxylase 65 (GAD-65) - Historically known positivity to any cell surface neuronal antibodies other than NMDAR and LGI1, in the absence of NMDAR and LGI1 antibody positivity - Confirmed paraneoplastic encephalitis - Confirmed central or peripheral nervous system demyelinating disease - Alternative causes of associated symptoms - History of herpes simplex virus encephalitis in the previous 24 weeks - Any previous/concurrent treatment with interleukin-6 (IL-6) inhibitory therapy (e.g., tocilizumab), alemtuzumab, total body irradiation, or bone marrow transplantation - Any previous treatment with anti-cluster of differentiation 19 antibody (CD19 antibody), complement inhibitors, neonatal Fc receptor antagonists, anti-B-lymphocyte stimulator monoclonal antibody - Any previous treatment with T-cell depleting therapies, cladribine, or mitoxantrone - Treatment with oral cyclophosphamide within 1 year prior to baseline - Treatment with any investigational drug (including bortezomib) within 24 weeks prior to screening - Concurrent use of more than one immunosuppressive therapy (IST) as background therapy - Contraindication to all of the following rescue treatments: rituximab, intravenous immunoglobulin (IVIG), high-dose corticosteroids, or intravenous (IV) cyclophosphamide - Any surgical procedure, except laparoscopic surgery or minor surgeries within 4 weeks prior to baseline, excluding surgery for thymoma or teratoma removal - Planned surgical procedure during the study - Evidence of progressive multifocal leukoencephalopathy - Evidence of serious uncontrolled concomitant diseases - Congenital or acquired immunodeficiency, including human immunodeficiency virus (HIV) infection - Active or presence of recurrent bacterial, viral, fungal, mycobacterial infection, or other infection - Infection requiring hospitalization or treatment with IV anti-infective agents within 4 weeks prior to baseline visit - Positive hepatitis B (HBV) and hepatitis C (HCV) test at screening - Evidence of latent or active tuberculosis (TB) - History of drug or alcohol abuse within 1 year prior to baseline - History of diverticulitis or concurrent severe gastrointestinal (GI) disorders that, in the investigator's opinion, may lead to increased risk of complications such as GI perforation - Receipt of live or live-attenuated vaccine within 6 weeks prior to baseline visit - History of blood donation (1 unit or more), plasma donation or platelet donation within 90 days prior to screening - History of severe allergic reaction to a biologic agent - History of suicide attempt within 3 years prior to screening except if this is clearly associated with and occurs during the acute phase of LGI-1 or NMDAR encephalitis - Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes safe participation in and completion of the study - Pregnant or breastfeeding, or intending to become pregnant during the study or within 3 months after the final dose of study drug

Study Design

Phase: Phase 3
Study Type: Interventional
Allocation: Randomized
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Arm Groups

Arm	Description	Assigned Intervention
Experimental NMDAR Autoimmune Encephalitis (AIE) Cohort	Adults and adolescents with definite or probable NMDAR encephalitis	Drug: Satralizumab In Part 1, study drug will be administered after all other study-related procedures have been performed at a site visit at Weeks 0, 2, 4, and every 4 weeks (Q4W) thereafter. Participants will receive satralizumab according to body weight. Study drug will be administered by subcutaneous (SC) injection in the abdominal or femoral region after all other study-related procedures have been performed at a site visit. In Part 2, participants will be asked to choose from one of the following options: Option 1: continue on randomized, double-blind study drug; Option 2: start open-label satralizumab based on body weight; Option 3: stop study treatment and continue follow-up assessments.
Experimental LGI1 AIE Cohort	Adults with LGI1 encephalitis	Drug: Satralizumab In Part 1, study drug will be administered after all other study-related procedures have been performed at a site visit at Weeks 0, 2, 4, and every 4 weeks (Q4W) thereafter. Participants will receive satralizumab according to body weight. Study drug will be administered by subcutaneous (SC) injection in the abdominal or femoral region after all other study-related procedures have been performed at a site visit. In Part 2, participants will be asked to choose from one of the following options: Option 1: continue on randomized, double-blind study drug; Option 2: start open-label satralizumab based on body weight; Option 3: stop study treatment and continue follow-up assessments.
Placebo Comparator NMDAR AIE Placebo Cohort	Adults and adolescents with definite or probable NMDAR encephalitis	Other: Placebo Satralizumab placebo prefilled syringe (PFS) is identical in composition to satralizumab PFS, but does not contain the satralizumab active ingredient and will be identical in appearance and packaging to satralizumab. A PFS (assembled with an needle safety device [NSD] and extended finger flange) filled with 0.5 milliliters (mL) of solution, corresponding to 60 milligrams (mg) satralizumab, may be used in Part 2 once it becomes available at the study site.
Placebo Comparator LGI1 AIE Placebo Cohort	Adults with LGI1 encephalitis	Other: Placebo Satralizumab placebo prefilled syringe (PFS) is identical in composition to satralizumab PFS, but does not contain the satralizumab active ingredient and will be identical in appearance and packaging to satralizumab. A PFS (assembled with an needle safety device [NSD] and extended finger flange) filled with 0.5 milliliters (mL) of solution, corresponding to 60 milligrams (mg) satralizumab, may be used in Part 2 once it becomes available at the study site.

Recruiting Locations

University of Alabama at Birmingham
Birmingham, Alabama 35233

More Details

Status: Recruiting
Sponsor: Hoffmann-La Roche

Study Contact

Reference Study ID Number: WN43174, https://forpatients.roche.com/
888-662-6728 (U.S.)
global-roche-genentech-trials@gene.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.